Table 4. Selection of ongoing OVs in clinical trials (with or without co-therapy) obtained from Clinicaltrials.gov.
Viral species | Variant | Genetic modification | Condition | Co-therapy | P | Identification number |
AdV | TILT-123 | TNF-B and IL-2 | Ovarian cancer | ICI | I | NCT05271318 |
AdVince | Chromogranin A and PTD [118] | NETs | NA | I/IIa | NCT02749331 | |
Theragene | CD and HSV-1 TK [119] | PC | Radiotherapy | IIa | NCT04739046 | |
YSCH-01 | L-IFN | Advanced solid tumors | NA | I | NCT05180851 | |
NG-641 | FAP-TAc and CXCL9/CXCL10/IFN-alpha | Metastatic cancers | Chemotherapy or ICI | I | NCT04053283 | |
HSV | G207 | Deletion of γ134.5 [120] | Cerebellar tumors | Radiotherapy | I | NCT03911388 |
OH2 | GM-CSF | Advanced PC | NA | Ib/II | NCT04637698 | |
ONCR-177 | IL-12, FLT3LG, CCL4 [121] | Advanced cutaneous and solid cancers | ICI | I | NCT04348916 | |
rRp450 | CYP2B1 and Deletion of ICP6 [122] | Primary LTs | NA | I | NCT01071941 | |
MV | MV-NIS | NIS | Recurrent medulloblastoma and ATRT | Surgery | I | NCT02962167 |
MV-s-NAP | NAP | Metastatic BC | NA | I | NCT04521764 | |
VV | GL-ONC1 | GUCB, B-gal and GFP [123] | LC and mesothelioma | NA | I | NCT01766739 |
MVA-MAGEA3 | MAGE-A3 | NSCLC | OV: ChAdOx-1-MAGEA3-NYESO, chemotherapy and ICI | I/II | NCT04908111 | |
JX-594 | GM-CSF and B-gal [124] | Advanced BC and sarcoma | Chemotherapy | I/II | NCT026330368 | |
Reovirus | Reolysin | NA | Relapsed or refractory MM | Chemotherapy | I | NCT02101944 |
Relapsed or refractory BTs | Recombinant GM-CSF | I | NCT02444549 | |||
NDV | MEDI5395 | GM-CSF [125] | Advanced solid tumors | Durvalumab | I | NCT03889275 |
VSV | VSV-hIFNbeta-NIS | IFN-beta and NIS | Stage IV or Recurrent Endometrial cancer | With or without chemotherapy | I | NCT03120624 |
VSV-GP128 | GP | Stage IV CRC | immunotherapy vaccines | I/II | NCT04046445 |